This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.
Compugen (NASDAQ:CGEN) focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. CGEN gets F’s in Equity and Cash Flow as well. Shares of the stock have declined 30.7% since January 1. This is worse than the Nasdaq, which has seen a 12.1% increase over the same period. For more information, get Portfolio Grader’s complete analysis of CGEN stock.
NovaGold Resources (AMEX:NG) explores and develops mineral properties in North America. NG also gets an F in Equity. Shares of the stock have declined 56.6% since January 1. For more information, get Portfolio Grader’s complete analysis of NG stock.
Sunesis Pharmaceuticals (NASDAQ:SNSS) is a clinical-stage biopharmaceutical Company which focuses on the discovery, development and commercialization of novel small molecule therapeutics for oncology. SNSS gets F’s in Earnings Growth, Earnings Momentum, Analyst Earnings Revisions, Equity, and Cash Flow as well. For more information, get Portfolio Grader’s complete analysis of SNSS stock.
AVEO (NASDAQ:AVEO) engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. AVEO also gets F’s in Earnings Growth, Earnings Momentum, Equity, Cash Flow, and Operating Margin Growth. Since January 1, AVEO has fallen 42.8%. For more information, get Portfolio Grader’s complete analysis of AVEO stock.
Navidea Biopharmaceuticals (AMEX:NAVB) is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. NAVB also gets an F in Equity. The stock has a trailing PE Ratio of 123.3. For more information, get Portfolio Grader’s complete analysis of NAVB stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
